Uxin shares drop 45% as predicted by InvestingPro’s Fair Value model
Patrick J. Haley, Executive Vice President, Commercial at Exelixis, INC. (NASDAQ:EXEL), sold a total of 72,231 shares of common stock on November 20 and 21, 2025, for approximately $3,046,928.
The sales occurred in multiple transactions with prices ranging from $41.77 to $42.58 per share. Specifically, on November 20, Haley sold 10,000 shares at a weighted average price of $42.11, 23,539 shares at a weighted average price of $41.93, and 10,648 shares at a weighted average price of $41.77. On November 21, Haley sold 28,043 shares at a weighted average price of $42.58.
Following these transactions, Haley directly owns 374,029 shares of Exelixis common stock, which includes shares that will be issued upon the vesting of restricted stock units (RSUs) and performance-based restricted stock units (PSUs).
In other recent news, Exelixis reported its third-quarter financial results for 2025, showcasing strong performance. The company achieved earnings per share (EPS) of $0.78, exceeding the forecasted $0.69. Additionally, Exelixis reported total revenue of $598 million, surpassing both Oppenheimer’s estimate of $584.0 million and the consensus forecast of $590.2 million. Despite these positive financial outcomes, Wolfe Research initiated coverage of Exelixis with a Peerperform rating, noting the company’s profitable cancer franchise but highlighting concerns about U.S. patent protection lasting only until January 2031. Oppenheimer maintained its Perform rating with a $36.00 price target on the company following the earnings report. These developments reflect the ongoing evaluation of Exelixis’ financial health and market position by analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.